8-K: Forte Biosciences Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences reported its third quarter 2024 financial results and provided an update on the clinical development of its lead drug candidate, FB102, including the start of a celiac disease trial.

Summary

• Forte Biosciences announced its third quarter 2024 financial results and provided a business update on November 14, 2024.
• The company is focused on developing FB102, a monoclonal antibody for autoimmune and autoimmune-related diseases.
• Forte has begun dosing patients in a celiac disease clinical trial for FB102, with topline data expected in the second quarter of 2025.
• In-vitro studies of FB102 showed significant inhibition of T and NK cell proliferation and activation.
• Non-human primate studies showed significant reductions in NK cell pharmacodynamic markers after a single dose of FB102.
• The phase 1 healthy volunteer trial for FB102 demonstrated a good safety profile and a significant reduction in the NK cell pharmacodynamic marker.
• Research and development expenses for the quarter were $5.9 million, down from $6.4 million in the same period of 2023.
• The decrease in R&D expenses was primarily due to a $3.0 million decrease in manufacturing costs, partially offset by a $2.5 million increase in clinical and other expenses.
• General and administrative expenses for the quarter were $2.8 million, down from $3.8 million in the same period of 2023.
• Net losses per share were $(4.54) for the three months ended September 30, 2024, compared to $(6.57) for the same period in 2023.
• Forte ended the third quarter with $16.4 million in cash and cash equivalents.
• In August 2024, Forte effected a 1:25 reverse stock split and has 1.46 million shares outstanding on a post-split basis as of September 30, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and some improvement in financial metrics, the significant cash burn and the need for future capital raises temper the overall sentiment.

Positives

• The company has made excellent progress with FB102 and has begun dosing patients in a celiac disease clinical trial.
• FB102 has shown promising results in preclinical studies, demonstrating selectivity in inhibiting the intermediate versus high affinity IL2 receptor.
• The phase 1 healthy volunteer trial for FB102 demonstrated a good safety profile.
• Research and development expenses decreased for the quarter and nine-month period compared to the same periods in 2023.
• Net losses per share improved for both the three and nine-month periods compared to the same periods in 2023.

Negatives

• The company experienced a net loss of $(8.392) million for the quarter and $(28.323) million for the nine-month period.
• General and administrative expenses increased for the nine-month period compared to the same period in 2023.
• The company's cash and cash equivalents decreased from $37.1 million at the end of 2023 to $16.4 million at the end of the third quarter 2024.

Risks

• The company's ability to obtain sufficient additional capital to continue to advance FB102 is a risk.
• There are uncertainties associated with the clinical development and regulatory approval of FB102, including potential delays in clinical trials.
• Results from preclinical and interim clinical trials may not be predictive of future results.
• There is a risk associated with the failure to realize any value from FB102 due to the inherent risks, expense, and difficulties involved in bringing product candidates to market.

Future Outlook

Forte plans to continue the patient trial in celiac disease with data expected in the second quarter of 2025 and is pursuing opportunities for FB102 across a variety of autoimmune and autoimmune-related diseases.

Management Comments

• Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences, stated that they continue to make excellent progress with FB102 and have begun dosing patients in a celiac disease clinical trial.
• He also mentioned that they are excited about the potential in celiac disease due to the biology of the disease and the mechanism of action of FB102.
• Management believes the data to date supports the significant potential for FB102 across a variety of autoimmune and autoimmune-related diseases.

Industry Context

The announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for autoimmune diseases. The progress of FB102 in clinical trials is being closely watched by investors and competitors in this space.

Comparison to Industry Standards

• Forte's focus on autoimmune diseases aligns with a growing trend in the biopharmaceutical industry, with companies like AbbVie (Humira), Johnson & Johnson (Stelara), and Bristol Myers Squibb (Orencia) having established successful franchises in this area.
• The development of monoclonal antibodies like FB102 is a common approach in this field, with many companies pursuing similar strategies.
• The reported reduction in NK cell pharmacodynamic markers is a positive sign, as this is a key target in many autoimmune therapies.
• The cash burn rate is a concern, as the company's cash reserves have decreased significantly, which is not uncommon for clinical-stage biopharma companies.
• The timeline for topline data in Q2 2025 is typical for a phase 2 trial, but the success of the trial will be critical for the company's future.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the clinical trials.
• Employees are impacted by the company's financial health and the progress of the FB102 program.
• Patients with autoimmune diseases may benefit from the development of FB102 if it proves to be effective.
• Creditors are impacted by the company's financial health and ability to repay debts.

Next Steps

• The company will continue the celiac disease patient trial for FB102.
• Topline data from the celiac disease trial is expected in the second quarter of 2025.
• Forte will continue to advance the FB102 program and pursue opportunities across a variety of autoimmune and autoimmune-related diseases.

Key Dates

Keywords

FB102, autoimmune diseases, celiac disease, clinical trial, monoclonal antibody, biopharmaceutical, research and development, financial results, NK cells, T cells